Hu's LaboratoryHu Wenhui Ph.D. Principal Investigator 2006.11 – present. Principal Investigator, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. 2002.12 – 2006.11. Postdoctoral fellow, Medicinal Chemistry, Center for drug discovery and chemical biology, Northwestern University Medical School, Chicago, IL. 1999.9 - 2002.7. Ph.D. Medicinal Chemistry, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 1992.9 - 1999.7. B.S. and M.S. Organic Chemistry, Shanxi University, Taiyuan, Shanxi, China. Personnel: Research:
The goal of Dr. Hu’s group is to identify drug candidates for further development by collaborating with scientific teams and big pharmaceutical company. His current research areas include anti-diabetic drug discovery (DDP-Ⅳ inhibitors), anti-alzheimer’s disease drug discovery (anti-neuroinflammatory inhibitors) and anti-inluenza drug discovery (M2 inhibitors). Currently, there are two drug candidates are under preclinical studies towards IND filling. Selected Publications and patents
1.Anti-influenza drug discovery |
● |
Xin Zhao, Chufang Li, Shaogao Zeng, Wenhui Hu*. Discovery of highly potent agents against influenza A virus. European Journal of Medicinal Chemistry. 2011, 46 (1):52-57. |
● |
Wenhui Hu*, Shaogao Zeng, Chufang Li,Yanling Jie, Zhiyuan Li and Ling Chen. Identification of Hits as Matrix-2 Inhibitors through the Focused Screening of a Small Primary Amine Library. Journal of Medicinal Chemistry. 2010, 53(9): 3831-3834. |
● |
CN200910030051.8 |
● |
CN200910031106.7 |
2.Anti-diabetic drug discovery |
● |
Jifeng Deng, Li Peng, Guicheng Zhang, Xiaobing Lan, Chufang Li, Fuxin Chen, Yayao Zhou, Zuoxian Lin, Ling Chen, Renke Dai, Hongjiang Xu, Ling Yang, Xiquan Zhang, Wenhui Hu*. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes. European Journal of Medicinal Chemistry. 2011, 46 (1): 71-76 |
● |
Li Li Zeng, Ying Jie Ding, Gui Cheng Zhang, Hong Rui Song, Wen Hui Hu*. A practical synthesis of trifluorophenyl R-amino acid: The key precursor for the new anti-diabetic drug sitagliptin. Chinese Chemical Letters. 2009, 20: 1397-1399. |
● |
CN200910024698.x |
● |
CN201010228604.3 |
3.Anti-alzheimer's disease drug discovery |
● |
Zhenbo Huang, Hao Wang, Xiurong Rao, Guifa Zhong, Wenhui Hu, Guoaing Sheng. Different effects of scopolamine on the retrieval of spatial memory and fear memory. Behavioural Brain Research. 2011 (221): 604–609. |
● |
Laura K Chico, Heather Behanna, Wenhui Hu, Guifa Zhong, Saktimayee Mitra Roy, and D. Martin Watterson. Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database. Drug metabolism and disposition. 2009, 37 (11): 2204-2211. |
● |
Lenka Munoz, Hantamalala Ralay Ranaivo, Saktimayee M. Roy, Wenhui Hu, Jeffrey M. Craft, Laurie K. McNamara, Linda J. Van Eldik and D. Martin Watterson. A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation. 2007, 4:21. |
● |
Wenhui Hu, Hantamalala Ralay Ranaivo, Saktimayee M. Roy, Heather A. Behanna, Laura K. Wing, Lenka Munoz, Ling Guo, Linda J. Van Eldik and D. Martin Watterson. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorganic & Medicinal Chemistry Letters. 2007, 17(2): 414-418. |
● |
Hantamalala Ralay Ranaivo, Jeffrey M. Craft, Wenhui Hu, Ling Guo, Laura K. Wing, Linda J. Van Eldik and D. Martin Watterson. Glia as a therapeutic target: attenuation of human Aß induced neuroinflammation and hippocampal deficits by oral administration of a selective inhibitor of glial activation. Journal of Neuroscience. 2006, 26(2): 662-670 |
● |
Wenhui Hu, Hantamalala Ralay Ranaivo, Jeffrey M. Craft, Linda J. Van Eldik, and D. Martin Watterson. Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer’s disease-related mouse model. Current Alzheimer Research. 2005, 2, 197-205. |
● |
Jeffrey M. Craft, Linda J. Van Eldik, Magdalena Zasadzki, Wenhui Hu and D. Martin Watterson. Aminopyridazines attenuate hippocampus dependent behavioral deficits induced by human A in a murine model of neuroinflammation. The Journal of Molecular Neuroscience. 2004, 24:115-122. |
● |
WO2007127448-A2; WO2007127375-A2; WO2007127474-A; WO2007130383-A2; WO2007127475-A2; WO2006050359-A2; WO2006050389-A2; US2004058977-A1; US2004029951-A1 |
4.Others: |
● |
Hong Li, Junling Zhao*,,Lili Zeng,and Wenhui Hu*. Organocatalytic Asymmetric Domino Aza-Michael-Mannich Reaction: Synthesis of Tetrahydroimidazopyrimidine Derivatives. The Journal of Organic Chemistry. J. Org. Chem. 2011, 76, 8064–8069 |
● |
Hong Li, Yingxue Liu, Qijun Liu, Wenhui Hu, Guochun Zhou. Synthesis of 2-amino-5-hydroxycaprolactam derivatives mediated by E-selective olefination and asymmetric oxidation of the enol ether. Synthesis. 2010, 23: 4068-4074. |
● |
Wenhui Hu, Zongru Guo, Xiang Yi, Changbin Guo, Fengming Chu and Guifang Cheng. Discovery of 2-Phenyl-3-sulfonylphenyl-indole derivatives as a new class of selective COX-2 inhibitors. Bioorganic & Medicinal Chemistry. 2003, 11(24): 5539-44. |
● |
Wenhui Hu, Zongru Guo, Fengming Chu, Aiping Bai, Xiang Yi, Guifang Cheng, Jing Li. Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: a new series of selective COX-2 inhibitors. Bioorganic & Medicinal Chemistry. 2003, 11(7), 1153-1160. |
● |
Wen Hui Hu, Zong Ru Guo, Ai Ping Bai, Zhi Bin Xu. A convenient synthesis of the substituted 2,3-diaryl-indole – the potent selective COX-2 inhibitors. Chinese Chemical Letters. 2002, 13(4): 296-298. |
|